Why the study?
Long noncoding RNAs regulate macrophage metabolism and plasticity in atherosclerotic inflammation, prompting a synthesis of recent findings to identify potential biomarkers and therapeutic targets.
Long noncoding RNAs modulate macrophage function and inflammation in atherosclerosis, presenting potential novel targets for disease biomarkers and therapeutic interventions.
Should not yet change practice; leaves open macrophage lncRNAs as AS biomarkers or therapeutic targets.
Chronic inflammation is part of the pathological process during atherosclerosis (AS). Due to the abundance of monocytes/macrophages within the arterial plaque, monocytes/macrophages have become a critical cellular target in AS studies. In recent decades, a number of long noncoding RNAs (lncRNAs) have been found to exert regulatory roles on the macrophage metabolism and macrophage plasticity, consequently promoting or suppressing atherosclerotic inflammation. In this review, we provide a comprehensive overview of lncRNAs in macrophage biology, highlighting the potential role of lncRNAs in AS based on recent findings, with the aim to identify disease biomarkers and future therapeutic interventions for AS.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: